 |
|
|
| |
Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Annalisa Marinosci
A. Marinosci * (1), D. Sculier (2), G. Wandeler (3), S. Yerly (4), M. Stoeckle (5), E. Bernasconi (6), D.L. Braun (7), P. Vernazza (8), M. Cavassini (9), M. Buzzi (10), L. Decosterd (9), P. Schmid (8), M. Branca (11), A. Limacher (11), M. Egger (12), H.F. Günthard (13), K.J. Metzner (14), A. Calmy (4)
Institutions
1-Hopitaux Universitaires de Genève, Infectious Diseases, Geneva, Switzerland, (2) Private office, Geneva, Switzerland, (3) Inselspital, Bern, Switzerland, (4) Hôpitaux Universitaires de Genève, Geneva, Switzerland, (5) University Hospital Basel, Basel, Switzerland, (6) Ospedale Regionale Lugano, Lugano, Switzerland, (7) University Hospital Zurich, Zurich, Switzerland, (8) Kantonsspital St. Gallen, St. Gallen, Switzerland, (9) Centre hospitalier universitaire vaudois, Lausanne, Switzerland, (10) Private Office, Geneva, Switzerland, (11) CTU, Bern, Switzerland, (12) University of Bern, Bern, Switzerland, (13) University Hospital of Zurich, Zurich, Switzerland, (14) University Hospital of Zuirch, Zurich, Switzerland
|
| |
|
|
|
|
|
